Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Weakens Into the Close
- Rice Midstream Partners LP (RMP) Names Jon Grimwood President, Announces Board Appointments
- Novelion Therapeutics (NVLN) Announces Acceptance of MAA for Metreleptin
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Management Changes, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!